Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Aybintio 25 mg/ml concentrate for solution for infusion
Medicines register · Ireland

Aybintio 25 mg/ml concentrate for solution for infusion

Authorisation EU/1/20/1454/002 · Samsung Bioepis NL B.V.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Samsung Bioepis NL B.V. (all products →)
Active substance
Bevacizumab
Clinical trials
437 clinical trials →
Dosage form
Concentrate for solution for infusion
Route of administration
Intravenous use
ATC code
L01XC07
First authorised
19/08/2020
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Bevacizumab: supply and approvals

11 authorised products on the HPRA list contain Bevacizumab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
Zirabev: Shortage resolved, first published 17 Jan 2025
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1454. It has been authorised for 6 years (since 19 August 2020). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Bevacizumab in Ireland

10 other products on the HPRA list contain Bevacizumab, from 10 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Abevmy 25 mg/mL concentrate for solution for infusionBiosimilar Collaborations Ireland LimitedCentralised EU authorisationNot stated
Alymsys 25 mg/mL concentrate for solution for infusionMabxience Research, S.L.Centralised EU authorisationNot stated
Avastin 25 mg/ml Concentrate for solution for infusionRoche Registration LimitedCentralised EU authorisationNot stated
Avastin 25 mg/ml concentrate for solution for infusionRoche Registration GmbHCentralised EU authorisationNot stated
Aybintio 25 mg/ml concentrate for solution for infusionSamsung Bioepis NL B.V.Centralised EU authorisationNot stated
Lytenava 25 mg/mL solution for injectionOutlook Therapeutics NL B.V.Centralised EU authorisationNot stated
MVASI 25 mg/mL Concentrate for solution for infusionAmgen Europe B.V.,Centralised EU authorisationNot stated
Oyavas 25 mg/mL concentrate for solution for infusionStada Arzneimittel AGCentralised EU authorisationNot stated
Vegzelma 25 mg/mL concentrate for solution for infusionCelltrion Healthcare Hungary Kft.Centralised EU authorisationNot stated
Zirabev 25 mg/ml concentrate for solution for infusionPfizer Europe MA EEIGCentralised EU authorisationNot stated

The licence holder

Samsung Bioepis NL B.V. holds 20 products on the HPRA list, with 10 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.